Eyewire+FDA Accepts Belite Bio’s NDA for Tinlarebant in Stargardt Disease

📋 Regulatory Action / Label Change

Belite Bio announced FDA acceptance of its NDA for tinlarebant in Stargardt disease type 1 (STGD1), a rare inherited retinal degeneration associated with ABCA4 mutations. The application received Priority Review with a PDUFA target action date of February 12, 2027.

Clinical Considerations

• The phase 3 DRAGON trial demonstrated a 35.7% reduction in atrophic retinal lesion growth versus placebo.
• Lesion progression was assessed using definitely decreased autofluorescence (DDAF) on fundus autofluorescence imaging.
• Tinlarebant was reported to be generally well tolerated, with adverse events consistent with its mechanism.
• If approved, tinlarebant would become the first FDA-approved treatment for Stargardt disease type 1.

Practice Applications

• Monitor FDA review milestones ahead of the February 2027 PDUFA date.
• Recognize Stargardt disease remains without approved pharmacologic therapies.
• Interpret DRAGON findings within the context of ongoing regulatory review.
• Consider potential implications for inherited retinal disease management if approved.